Department of Neurosurgery, Tianjin Medical University General Hospital, Tianjin 300052, PR China.
Department of Molecular Imaging and Nuclear Medicine, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, PR China.
Brain Res. 2024 Sep 1;1838:149011. doi: 10.1016/j.brainres.2024.149011. Epub 2024 May 18.
Spinal Cord Injury (SCI) is a debilitating disease associated with a significant economic burden owing to its high level of disability; however, current treatment options have only limited efficacy. Past research has shown that iron-dependent programmed cell death, also known as ferroptosis, plays a critical role in the pathogenesis of SCI. The sigma-1 receptor (Sig-1R) is widely distributed in the central nervous system, and has been implicated in the pathophysiology of several neurological and psychiatric disorders. Several in vivo and ex vivo studies have shown that Sig-1R activation exerts unique neuroprotective effects. However, the underlying mechanisms remain unclear. To date, no study has yet demonstrated the association between Sig-1R activation and ferroptosis in patients with SCI. However, the present study found that Sig-1R activation effectively promoted the recovery of motor function in mice after spinal cord injury, attenuated neuronal apoptosis, reduced the production of pro-inflammatory cytokines and iron accumulation, and inhibited ferroptosis in spinal cord tissues following SCI in mice. Ferroptosis and IRE1α were significantly upregulated after spinal cord injury, while sigma-1 receptor agonists were able to facilitate this result through the elimination of inositol-requiring enzyme-1 alpha (IRE1α)-mediated neuronal ferroptosis. Therefore, sigma-1 receptor activation could attenuate ferroptosis after SCI by reducing IRE1α and improving functional recovery after SCI, potentially representing a new therapeutic strategy for treating SCI.
脊髓损伤 (SCI) 是一种使人衰弱的疾病,由于其高残疾水平,带来了巨大的经济负担;然而,目前的治疗选择仅具有有限的疗效。过去的研究表明,铁依赖性程序性细胞死亡,也称为铁死亡,在 SCI 的发病机制中起着关键作用。西格玛-1 受体 (Sig-1R) 在中枢神经系统中广泛分布,并与几种神经和精神疾病的病理生理学有关。几项体内和体外研究表明,Sig-1R 激活发挥独特的神经保护作用。然而,其潜在机制尚不清楚。迄今为止,尚无研究表明 Sig-1R 激活与 SCI 患者的铁死亡之间存在关联。然而,本研究发现 Sig-1R 激活可有效促进 SCI 后小鼠运动功能的恢复,减轻神经元凋亡,减少促炎细胞因子的产生和铁积累,并抑制 SCI 后小鼠脊髓组织中的铁死亡。SCI 后铁死亡和 IRE1α 明显上调,而西格玛-1 受体激动剂通过消除肌醇需求酶 1α(IRE1α)介导的神经元铁死亡来促进这一结果。因此,Sig-1R 激活通过减少 IRE1α 并改善 SCI 后的功能恢复,可以减轻 SCI 后的铁死亡,这可能代表治疗 SCI 的一种新的治疗策略。